



Anika to Present at the Singular Research 11th Annual Spring Select Conference on June 9, 2016

BEDFORD, Mass.--(BUSINESS WIRE)-- **Anika Therapeutics, Inc.**, (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary **hyaluronic acid ("HA") technology**, today announced that its President and Chief Executive Officer, Charles H. Sherwood, Ph.D., will make a presentation at the Singular Research 11th Annual Spring Select Conference on Thursday, June 9, 2016 at 2:30 pm PT. The conference is being held at the Hilton hotel in San Francisco, CA.

A live audio webcast of the presentation may be accessed via the "**Investor Relations**" section of Anika's website at www.anikatherapeutics.com. An audio archive of the presentation also will be available on the website.

About Anika Therapeutics, Inc.

Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated orthopedics medicines company based in Bedford, Mass. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions by providing clinically meaningful therapeutic pain management solutions along the continuum of care, from palliative care to regenerative medicine. The Company has over two decades of expertise developing, manufacturing and commercializing more than 20 products, in markets across the globe, based on its proprietary **hyaluronic acid (HA) technology**. Anika's orthopedic medicine portfolio is comprised of marketed (**ORTHOVISC®** and **MONOVISC®**) and pipeline (**CINGAL®** and **HYALOFAST®** in the U.S.) products to alleviate pain and restore joint function by replenishing depleted HA and aiding cartilage repair and regeneration. For more information about Anika, please visit <http://www.anikatherapeutics.com>.

▪

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20160602005703/en/>

For Investor Inquiries:
Anika Therapeutics, Inc.
Sylvia Cheung, 781-457-9000
Chief Financial Officer

or

For Media Inquiries:
Pure Communications
Susan Heins, 864-286-9597

Source: Anika Therapeutics, Inc.

News Provided by Acquire Media
